Cargando…

The path to hepatitis C elimination: who are we leaving behind and why?

Detalles Bibliográficos
Autores principales:	Rockstroh, Jurgen K., Swan, Tracy, Chang, Judy, Elamouri, Fauzi, Lloyd, Andrew R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Viewpoint
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10371387/ https://www.ncbi.nlm.nih.gov/pubmed/37494827 http://dx.doi.org/10.1002/jia2.26136

Ejemplares similares

Leaving no one behind: Towards equitable global elimination of hepatitis C
por: Dahl, Elin Hoffmann, et al.
Publicado: (2020)

World Mental Health Day 2023: We must leave no one behind in the response to HIV and mental health
por: Wainberg, Milton L., et al.
Publicado: (2023)

Ending unjust HIV criminalization: leave no‐one behind
por: Bernard, Edwin J, et al.
Publicado: (2021)

The evolving schistosomiasis agenda 2007-2017—Why we are moving beyond morbidity control toward elimination of transmission
por: King, Charles H.
Publicado: (2017)

Why Are We Not There Yet?
por: Wenger, Nanette K.
Publicado: (2021)

Sehat sahulat: A social health justice policy leaving no one behind
por: Forman, Rebecca, et al.
Publicado: (2022)

Leaving no one behind: Pakistan’s risk communication and community engagement during COVID-19
por: Haq, Zaeem ul, et al.
Publicado: (2021)

Ensuring no one is left behind: Urgent action required to address implementation challenges for NTD control and elimination
por: Krentel, Alison, et al.
Publicado: (2018)

COVID-19 in India: Who are we leaving behind?
por: Raju, Emmanuel, et al.
Publicado: (2021)

Leave no one behind: inclusion of alpha-1 antitrypsin deficiency patients in COVID-19 vaccine trials
por: Yang, Chengliang, et al.
Publicado: (2022)

Progress towards elimination goals for viral hepatitis
por: Cox, Andrea L., et al.
Publicado: (2020)

Why Reducing Low-Value Care Fails to Bend the Cost Curve, and Why We Should Do it Anyway
por: Kroon, Daniëlle, et al.
Publicado: (2023)

First WHO Meeting of Stakeholders on Elimination of Gambiense Human African Trypanosomiasis
por: Holmes, Peter
Publicado: (2014)

Hepatitis C virus elimination: time for disruptive innovation
por: Klein, Marina B
Publicado: (2019)

Re-thinking resuscitation: leaving blood pressure cosmetics behind and moving forward to permissive hypotension and a tissue perfusion-based approach
por: Dünser, Martin W, et al.
Publicado: (2013)

Why Are Digital Health Care Systems Still Poorly Designed, and Why Is Health Care Practice Not Asking for More? Three Paths Toward a Sustainable Digital Work Environment
por: Persson, Johanna, et al.
Publicado: (2021)

Prevention of cardiovascular disease: why do we neglect the most potent intervention?
por: Stamatakis, Emmanuel, et al.
Publicado: (2009)

Brexit and health security: why we need to protect our global networks
por: Solomon, Danielle
Publicado: (2019)

Why do we need international standards on responsible research publication for authors and editors?
por: Wager, Elizabeth, et al.
Publicado: (2013)

The role of the Primary Healthcare Network in Iran in hepatitis C virus elimination by 2030
por: Behzadifar, Masoud, et al.
Publicado: (2018)

Hepatitis C elimination in people living with HIV – the importance of biomedical and behavioural interventions
por: van Santen, Daniela K, et al.
Publicado: (2020)

Why We Are Losing the War Against COVID-19 on the Data Front and How to Reverse the Situation
por: Prieto-Merino, David, et al.
Publicado: (2021)

Strengthening global commitment to eliminating cervical cancer: What lessons from the past can we apply to the future?
por: Taghavi, Katayoun, et al.
Publicado: (2020)

Why machine learning (ML) has failed physical activity research and how we can improve
por: Fuller, Daniel, et al.
Publicado: (2022)

Following the Path
por: Freeman, Wilbur K.
Publicado: (2020)

Viral Hepatitis Strategic Information to Achieve Elimination by 2030: Key Elements for HIV Program Managers
por: Hutin, Yvan, et al.
Publicado: (2017)

The need for a European hepatitis C programme monitoring resistance to direct-acting antiviral agents in real life to eliminate hepatitis C
por: Popping, Stephanie, et al.
Publicado: (2018)

Drugs that target early stages of Onchocerca volvulus: A revisited means to facilitate the elimination goals for onchocerciasis
por: Jawahar, Shabnam, et al.
Publicado: (2021)

Why we should all be more careful in drawing conclusions about how COVID-19 is changing drug markets
por: Giommoni, Luca
Publicado: (2020)

The impact of COVID-19 pandemic on AIDS-related mycoses and fungal neglected tropical diseases: Why should we worry?
por: Nargesi, Sanaz, et al.
Publicado: (2021)

Control of Urban Zika Vectors: Should We Return to the Successful PAHO/WHO Strategy?
por: Reiter, Paul
Publicado: (2016)

Decoded: The Science Behind Why We Buy
por: Barden, Phil
Publicado: (2013)

COVID-19: Why Declining Biodiversity Puts Us at Greater Risk for Emerging Infectious Diseases, and What We Can Do
por: Khetan, Aditya K.
Publicado: (2020)

A call to action for universal health coverage: Why we need to address gender inequities in the neglected tropical diseases community
por: Ozano, Kim, et al.
Publicado: (2020)

The path to find an HIV vaccine
por: Gray, Glenda E, et al.
Publicado: (2021)

The path to equitable HIV prevention
por: Idoko, John Alechenu, et al.
Publicado: (2022)

Cracking the code: unveiling the specific and shared mechanisms behind musculoskeletal interventions
por: McDevitt, Amy W., et al.
Publicado: (2023)

Why Biological Psychiatry Hasn’t Delivered Yet – and Why Neurology Knows
por: Frisch, Stefan
Publicado: (2021)

List of essential psychotherapeutic medicines 2019 of India: When science was left behind
por: Parmar, Arpit, et al.
Publicado: (2022)

Antibodies for HIV prevention: the path forward
por: Malhotra, Shelly, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ovo0baifmd1kg0jqd7m8f7qft4